InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

REPLIGEN CORP

RGEN Clue Score51
United States Fiscal year ends December CIK 0000730272 Results filed 27 Oct 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

10
Insider
Date
Role
Action
Shares
Price
Amount
Glenn P Muir
7 May 2026
Director
Exercised, kept
2,434
$38.76
$94.34K
Glenn P Muir
16 Dec 2025
Director
Exercised, kept
3,366
$26.12
$87.92K
Anthony Hunt
5 Dec 2024
Director
Exercised, kept
11,808
$33.87
$399.94K
Glenn P Muir
19 Nov 2024
Director
Exercised, kept
19,000
$36.29
$689.51K
Glenn P Muir
1 Aug 2024
Director
Exercised, kept
5,000
$36.29
$181.45K
Karen A Dawes
14 Jun 2024
Director
Exercised, kept
2,953
$67.71
$199.95K
Jon Snodgres
7 Oct 2022
Chief Financial Officer
Exercised, kept
466
$59.52
$27.74K
Jon Snodgres
8 Mar 2022
Chief Financial Officer
Exercised, kept
1,214
$59.52
$72.26K
Jon Snodgres
8 Mar 2022
Chief Financial Officer
Exercised, kept
2,952
$33.87
$99.98K
Jon Snodgres
25 Jan 2021
Chief Financial Officer
Exercised, kept
4,000
$33.87
$135.48K
Showing 250 of 369 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 354
Amendments (4/A) skipped 15
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 160
Sales at will 170
Transactions with no price 0
Shares from compensation/vesting 3,091,951
Sales filed before the plan box existed 166
History held since 6 Dec 2006